The May issue of Nature Biotechnology contains a feature article analyzing the private biotech sector. This is a sister article, of sorts, to the public biotech sector feature we’ve been running for years, and it’s a piece we’ve run in the past. Like the public biotech article, we’ve made this one free, though for just a month. You can access it here (PDF is here), and be sure to view the supplementary information that goes along with it. The article is data heavy, for which we are thankful for Dow Jones/VentureSource for providing the numbers.